263 related articles for article (PubMed ID: 16344613)
1. New approaches in the treatment of Adamantiades-Behçet's disease.
Pipitone N; Olivieri I; Cantini F; Triolo G; Salvarani C
Curr Opin Rheumatol; 2006 Jan; 18(1):3-9. PubMed ID: 16344613
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Adamantiades-Behçet disease with systemic interferon alfa.
Zouboulis CC; Orfanos CE
Arch Dermatol; 1998 Aug; 134(8):1010-6. PubMed ID: 9722733
[TBL] [Abstract][Full Text] [Related]
3. Behçet's disease: a new target for anti-tumour necrosis factor treatment.
Sfikakis PP
Ann Rheum Dis; 2002 Nov; 61 Suppl 2(Suppl 2):ii51-3. PubMed ID: 12379622
[TBL] [Abstract][Full Text] [Related]
4. The use of biologic agents in the treatment of ocular manifestations of Behcet's disease.
Benitah NR; Sobrin L; Papaliodis GN
Semin Ophthalmol; 2011; 26(4-5):295-303. PubMed ID: 21958178
[TBL] [Abstract][Full Text] [Related]
5. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
[TBL] [Abstract][Full Text] [Related]
6. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
Accorinti M; Pirraglia MP; Paroli MP; Priori R; Conti F; Pivetti-Pezzi P
Jpn J Ophthalmol; 2007; 51(3):191-6. PubMed ID: 17554481
[TBL] [Abstract][Full Text] [Related]
7. Behçet's syndrome: from aetiology to treatment.
Powell RJ
Adv Exp Med Biol; 2003; 528():481-6. PubMed ID: 12918749
[No Abstract] [Full Text] [Related]
8. Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients.
Arida A; Fragiadaki K; Giavri E; Sfikakis PP
Semin Arthritis Rheum; 2011 Aug; 41(1):61-70. PubMed ID: 21168186
[TBL] [Abstract][Full Text] [Related]
9. A patient with neuro-Behçet's disease is successfully treated with etanercept: further evidence for the value of TNFalpha blockade.
Alty JE; Monaghan TM; Bamford JM
Clin Neurol Neurosurg; 2007 Apr; 109(3):279-81. PubMed ID: 17174468
[TBL] [Abstract][Full Text] [Related]
10. Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease.
Park J; Cheon JH
Gut Liver; 2018 Nov; 12(6):623-632. PubMed ID: 29788675
[TBL] [Abstract][Full Text] [Related]
11. [Adamantiades-Behcet's disease].
Krause L
Ophthalmologe; 2005 Apr; 102(4):329-34. PubMed ID: 15668761
[TBL] [Abstract][Full Text] [Related]
12. Adamantiades-Behçet's disease therapy: current treatment options and recommendations with regard to the COVID-19 pandemic.
Trevisini S; Trevisan G; Zalaudek I; Bonin S
Dermatol Ther; 2022 Mar; 35(3):e15286. PubMed ID: 34962035
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of etanercept in the treatment of a patient with Behçet's disease.
Curigliano V; Giovinale M; Fonnesu C; Cerquaglia C; Verrecchia E; Turco S; Manganelli C; Manna R
Clin Rheumatol; 2008 Jul; 27(7):933-6. PubMed ID: 18330611
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of life-threatening intestinal ulcer in Behçet's disease with infliximab: rapid healing of Behçet's ulcer with infliximab.
Ju JH; Kwok SK; Seo SH; Yoon CH; Kim HY; Park SH
Clin Rheumatol; 2007 Aug; 26(8):1383-5. PubMed ID: 17039261
[TBL] [Abstract][Full Text] [Related]
15. Case of neuro-Behçet's disease successfully maintained a remission using infliximab for 2 years.
Kanemaru H; Makino T; Jinnin M; Yonemitsu A; Makino K; Ihn H
J Dermatol; 2013 Aug; 40(8):632-4. PubMed ID: 23724912
[TBL] [Abstract][Full Text] [Related]
16. Laryngeal involvement in Behcet's disease--a challenge for treatment.
Gross M; Ben-Chetrit E
Clin Rheumatol; 2013 Mar; 32 Suppl 1():S75-7. PubMed ID: 20532579
[TBL] [Abstract][Full Text] [Related]
17. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease.
Sugimura N; Mizoshita T; Sugiyama T; Togawa S; Miyaki T; Suzuki T; Tanida S; Kataoka H; Sasaki M
Dig Liver Dis; 2019 Jul; 51(7):967-971. PubMed ID: 30872086
[TBL] [Abstract][Full Text] [Related]
18. Mycophenolate mofetil is ineffective in the treatment of mucocutaneous Adamantiades-Behçet's disease.
Adler YD; Mansmann U; Zouboulis CC
Dermatology; 2001; 203(4):322-4. PubMed ID: 11752821
[TBL] [Abstract][Full Text] [Related]
19. An incomplete form of childhood Behçet's disease treated with infliximab.
Caporuscio S; Pranteda G; Nistico S; Maucione T; Canzoni M; Stefani A; Muscianese M; Fanto M; Sorgi M
Int J Immunopathol Pharmacol; 2014; 27(3):445-8. PubMed ID: 25280037
[TBL] [Abstract][Full Text] [Related]
20. A case of mucocutaneous Behçet's disease responding to etanercept.
Sommer A; Altmeyer P; Kreuter A
J Am Acad Dermatol; 2005 Apr; 52(4):717-9. PubMed ID: 15793540
[No Abstract] [Full Text] [Related]
[Next] [New Search]
